Skip to main content
Science / Explained
SERIES: What We Don’t KnowArticle 2 of 6
The same GLP-1 dose produces different results in different people

Two patients on identical GLP-1 doses can lose dramatically different amounts of weight. One might lose 8 percent of their body weight while another loses 22 percent. The difference is not random, and it is not about willpower.

The answer appears to live in biology no one can test for yet.

Gut bacteria, genetics, and the way the body has managed weight over time all appear to shape how strongly someone responds. These factors seem to interact in ways that make one person's metabolism different from the next. But there is no predictive test. There is no way to know beforehand who will be a strong responder and who will be a modest one.

Doctors prescribe the same dose to everyone and then watch what happens. If the response is weak, they might increase it. If side effects are strong, they might lower it. But the early difference in outcome starts with biology that science has not yet mapped.

This individual variation is one of the most important unsolved questions in GLP-1 research. Understanding it could mean prescribing the right dose from the start instead of adjusting by trial and error. It could mean matching patients to the right compound for their unique metabolism.

Some of that variation may trace back to the microbiome, the trillions of bacteria that live in the gut and influence how the body processes food and signals. GLP-1 agonists appear to reshape these bacteria, and the bacteria appear to reshape how much GLP-1 the body makes naturally.

The loop runs in both directions, and we are just starting to map it.

OneMoreThing

The answer may live in the gut, not the genes.

Emerging research shows that gut bacteria composition influences how the body processes GLP-1 peptides.Different bacterial populations produce different levels of short-chain fatty acids.Those fatty acids affect how sensitive GLP-1 receptors are.

Two patients with identical genetics but different microbiomes may respond completely differently to the same dose.Precision medicine for metabolic peptides may not start with a blood test.It may start with a stool sample.

← Previous
GLP-1 reaches brain circuits beyond appetite
Next →
Years on GLP-1 leave marks on the brain we are still mapping
References7 sources

How to read these sources

This article uses primary sources and reviews to separate mechanism, human evidence, and context.

Human TrialStudies in people
ReviewExpert synthesis
Show 3 more source types
Official LabelRegulator documents
MechanismCell and pathway logic
Public UpdateNews or announcements
  1. Human TrialMassachusetts Medical Society

    Wilding JPH, Batterham RL, Calanna S, et al. · 2021 Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). Read source

    Used Here For

    Providing the waterfall-plot data showing how much individual weight-loss response varies with semaglutide.

    Good For

    Human evidence on the spread of individual responses, not just the average result.

    Not For

    Predicting exactly where one person will land on that response curve.

    N Engl J Med 384(11):989-1002, waterfall plot demonstrates inter-patient response distribution
    PMID 33567185DOI 10.1056/NEJMoa2032183
  2. Human TrialMassachusetts Medical Society

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. · 2022 Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). Read source

    Used Here For

    Providing the pivotal trial data on tirzepatide's average and individual-level weight-loss response.

    Good For

    Human efficacy and safety data for tirzepatide at approved trial doses.

    Not For

    Head-to-head comparison with other drugs or off-label dosing.

    N Engl J Med 387(3):205-216
    PMID 35658024DOI 10.1056/NEJMoa2206038
  3. Human Trial

    Scientific Reports

    Springer Nature

    Klemets A, Reppo I, Krigul KL, Volke V, Aasmets O, Org E. · 2026 Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake. Read source

    Used Here For

    Supporting the idea that gut-microbiome composition may help predict semaglutide response.

    Good For

    Early human evidence linking the microbiome to treatment-response variation.

    Not For

    Drawing firm conclusions from a small (n=20) study without larger replication.

    Sci Rep 16(1):6126, first prospective study testing microbiome as predictor of semaglutide response (n=20, T2D)
    PMID 41580554
  4. Review

    Cell

    Cell Press (Elsevier)

    Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. · 2016 From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Read source

    Used Here For

    Explaining how gut bacteria's fiber-derived metabolites influence host metabolism, background for response variation.

    Good For

    Foundational understanding of short-chain fatty acids as bacterial-host signals.

    Not For

    Direct evidence about GLP-1 drug response.

    Cell 165(6):1332-1345
    PMID 27259147DOI 10.1016/j.cell.2016.05.041
  5. Human TrialSpringer Nature

    Depommier C, Everard A, Druart C, et al. · 2019 Supplementation with Akkermansia muciniphila in overweight and obese human volunteers. Read source

    Used Here For

    Providing human evidence that a specific gut bacterium can shift metabolic markers, supporting the microbiome-variation angle.

    Good For

    Human trial data on a probiotic intervention's metabolic effects.

    Not For

    Concluding this bacterium predicts or improves GLP-1 drug response specifically.

    Nat Med 25(7):1096-1103
    PMID 31263284DOI 10.1038/s41591-019-0495-2
  6. Human Trial

    PeerJ

    PeerJ Inc.

    Shang J, Liu F, Zhang B, Dong K, et al. · 2021 Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus. Read source

    Used Here For

    Showing liraglutide use is associated with gut-microbiota changes in people with type 2 diabetes.

    Good For

    Human evidence that GLP-1 drugs and gut bacteria composition are linked.

    Not For

    Establishing that microbiota change causes the treatment response.

    PeerJ 9:e11128
    PMID 33850659
  7. Human Trial

    Diabetes & Metabolism

    Elsevier

    Smits MM, et al. · 2021 Counter-evidence: Liraglutide did NOT alter microbial diversity in this RCT (n=51). Read source

    Used Here For

    Including a contrasting null result — a well-powered RCT that found no liraglutide effect on microbial diversity — for honest, balanced framing.

    Good For

    A check against overclaiming the microbiome-GLP-1 link from smaller positive studies.

    Not For

    Assuming this null result rules out any microbiome role in individual variation.

    Diabetes Metab 47(5):101223, null result included for honest framing
    PMID 33429063